Advertisement

Topics

Patricia Nash Company Profile

06:39 EDT 20th September 2018 | BioPortfolio

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The company was founded in 2012 by the designer Patricia Nash who was inspired by her extensive international travels and vintage handbags found in her mother’s closet. The collection pays homage to Old World craftsmanship through delicate, hand-finished detailing including hand-dying, hand-cutting, hand-sewing and a hand-embossed logo in every design. Patricia Nash Designs is based in Knoxville, TN, and sold in major retail department stores nationwide.


News Articles [299 Associated News Articles listed on BioPortfolio]

Patricia Anne Burton

bmj;361/apr09_6/k1490/FAF1faAfter lecturer posts at University College London and Edinburgh University, Patricia Anne Burton (“Pat”) completed her training in pathology at Newcastle. In 1973 she.....

Continental Who's Who recognizes Patricia L. Collins, MBA

BUFFALO, N.Y., Sept. 12, 2018 /PRNewswire/ -- Continental Who's Who recognizes Patricia L. Collins, MBA, as a Pinnacle Lifetime Member in the field of Real Read more...

[Comment] FGF-19 agonism for NASH: a short study of a long disease

Non-alcoholic steatohepatitis (NASH) has emerged as the most common cause of liver disease worldwide and is on a trajectory to become the most common indication for liver transplantation.1,2 Interest ...

Startup Terns Secures Three NASH Assets From Eli Lilly

The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three ...

Drs. Jonathan and Kenneth Nash Treat Gum Disease in Vicksburg, MS with Modern Laser Dentistry, Honor National Gum Care Month

VICKSBURG, MS (PRWEB) September 13, 2018 Nash Family Dentistry team, Drs. Jonathan Nash and Kenneth Nash, are honoring National Gum ...

NASH Cirrhosis: The Real NASH Epidemic

AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition

Along with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space...   

First International NASH Day is a Call to Action

The prevalence of nonalcoholic steatohepatitis (NASH) is increasing across the globe and is expected to be the leading indication for liver transplants by 2020. Despite that, awareness of the disease ...

PubMed Articles [101 Associated PubMed Articles listed on BioPortfolio]

Nonalcoholic steatohepatitis in posttransplantation liver: Review article.

Nonalcoholic steatohepatitis (NASH) associated or not with cirrhosis is the third leading indication for liver transplantation (LT) around the world. After transplants, NASH has a high prevalence and ...

Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States.

Non-alcoholic steatohepatitis (NASH) is the progressive form of non-alcoholic fatty liver disease (NAFLD). Our aim was to estimate the total economic burden of NASH and advanced NASH in the United Sta...

Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score.

Nonalcoholic steatohepatitis (NASH) is an important etiology of end-stage liver disease. Long-term effect of bariatric surgery in improvement of NASH is not clear.

Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) can advance, if untreated, to liver fibrosis, cirrhosis, hepatocellular carcinoma, liver failure and liver-related de...

A long-acting FGF21 alleviates hepatic steatosis and inflammation in NASH mice partly through an FGF21- adiponectin- IL17A axis.

NASH is the most severe form of NAFLD and is a serious public health problem around the world. There are currently no approved treatments for NASH. FGF21 has recently emerged as a promising drug candi...

Clinical Trials [158 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis (BEAT-NASH)

Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is no cure for NASH.Prevention of...

Companies [39 Associated Companies listed on BioPortfolio]

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

Nash Finch Company

North American Specialty Hospital

Headquartered in Denver, NASH is a US majority-owned and managed enterprise. Incorporating US physicians in its service delivery, NASH is designed to provide pre-operative and pos...

HARVEY NASH GROUP

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the m...

Jecure Therapeutics

Jecure is focused on the discovery of novel therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure’s scientific founder is Dr. Arie...

More Information about "Patricia Nash" on BioPortfolio

We have published hundreds of Patricia Nash news stories on BioPortfolio along with dozens of Patricia Nash Clinical Trials and PubMed Articles about Patricia Nash for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Patricia Nash Companies in our database. You can also find out about relevant Patricia Nash Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record